Wnts are a highly conserved family of lipid-modified glycoproteins that work as morphogens to activate several signaling pathways, leading to remodeling of the cytoskeleton and the regulation of gene transcription. Wnt signaling regulates multiple cellular functions and cell systems, including the development and maintenance of midbrain dopaminergic (mDA) neurons. These neurons are of considerable interest for regenerative medicine because their degeneration results in Parkinson's disease (PD). This review focuses on new advances in understanding key functions of Wnts in mDA neuron development and using novel tools to regulate Wnt signaling in regenerative medicine for PD. Particularly, recent reports indicate that appropriate levels of Wnt signaling are essential to improve the quantity and quality of stem cell-or reprogrammed cell-derived mDA neurons to be used in drug discovery and cell replacement therapy for PD.
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The Wnt/calcium pathway is generally activated by Wnt5a or Wnt11 binding to the Fz receptor, followed by recruitment of Dvl. This pathway is thought to involve trimeric G proteins, the activation of phospholipase C, and the generation of diacylglycerol and Inositol 1,4,5 triphosphate (IP3). This leads to the release of calcium from intracellular stores, which in turn activates calcium-sensitive proteins such as protein kinase C (PKC), calciumcalmodulin-dependent kinase II (CamKII), calpain, and the phosphatase calcineurin, leading to the regulation of the nuclear factor of activated T cells (NFAT) (Gao and Chen, 2010; Kikuchi et al., 2011) . Notably, NFAT positively regulates neurogenesis by binding Dvl and inhibiting Wnt/-catenin signaling (Huang et al., 2012) , and CamKII regulates dendritic spines and synaptic strength (Ciani et al., 2011) .
The Wnt/PCP pathway is the most complex Wnt pathway, which functions to establish asymmetrical distribution of proteins within a cell in order to organize polarity of the cells in a cell layer or plane. This pathway is generally activated by Wnt5a or Wnt11 by binding to Fz2, 3, 6, or 7 alone or together with a co-receptor. Multiple Wnt/PCP co-receptors have been described, including the tyrosine kinase receptors Ror1/2 and Ryk, Protein tyrosine kinase 7 (PTK7), Syndecan, and Glypican 4/6. Core components of the Drosophila PCP pathway are conserved in mammals, including Fz, two transmembrane proteins Van Goghlike 1 and 2 (Vangl1/2) and Cadherin, EGF, LAG seven-pass G-type receptors 1−3(Celsr1−3), and cytoplasmic signaling components Dvl1−3, prickle1/2 (Pk1/2), and Diversin or Inversin (Gray et al., 2011; Kikuchi et al., 2011) . In Drosophila, Fz directly interacts with core PCP components present in distal membranes (Dvl and Celsr−Inversin) rather than Vangl−Pk present in proximal membranes. However, in mammals, it is more possible that Wnt−Fz interacts indirectly with Vangl2 via Wnt co-receptors, such as Ror2 (Gao et al., 2011) or Ryk (Andre et al., 2012) . The scaffolding protein Dvl has been found to interact with multiple signaling components including other core PCP components (Celsr, Inversin, Vangl, and Pk) and Wnt/PCP co-receptors (Ryk, Musk, PTK7, and Syndecan) (Gao and Chen, 2010) . Thus a wide array of complexes is formed to define different Wnt/PCP signaling. It should be noted that the interaction of Wnt−Fz with some co-receptors (Ryk, PTK7, and 6 associated activator of morphogenesis 1) becomes active after binding to Dvl. Both Dvl and Daam1 interact with the guanine nucleotide exchange factor (GEF), which is called weaksimilarity GEF (WGEF), to form a Rho-GTP complex that in turn activates ROCK kinase and remodels the cytoskeleton (Habas et al., 2001) . In a Dvl−Rac1−JNK pathway, Dvl interacts directly with Rac1 (Ras-related C3 botulinum toxin substrate 1) and the Rac1 GEF, Tiam1 (T-cell lymphoma invasion and metastasis 1) to form a Rac1-GTP complex (Cajanek et al., 2013) , a process that requires -arrestin and can be inhibited by Casein kinase 1/1/2 (Bryja et al., 2008) . Rac1 in turn activats the downstream effector c-Jun N-terminal kinase (JNK) to regulate processes, such as dendrite growth (Rosso et al., 2005) and cell polarity movements during gastrulation (Habas et al., 2003) . It has also been reported that Cdc42 activated by Wnt5a via Ror2 and PI3 kinase mediate the JNK signaling cascade via the transcription factors ATF2 and c-Jun to regulate the expression of paraxial protocadherin and convergent extension in Xenopus (Schambony and Wedlich, 2007) .
These Wnt pathways interact with one another at multiple levels, because they share ligands and the Fz−Dvl module, and also because there are multiple mechanisms for Wnt/-catenin-independent pathways to block Wnt/-catenin pathways, such as the Wnt5a-induced activation of Siah, a ubiquitin E3 ligase that degrades -catenin (Topol et al., 2003) or the inhibition of Dvl by NFAT (Huang et al., 2012) . Converse mechanisms to inhibit Wnt/-catenin-independent pathways by Wnt/-catenin-dependent pathways also exist.
For instance, Lrp5/6 prevents the activation of the Wnt/PCP/Rac1 pathway and its deletion leads to neural tube closure defects (Bryja et al., 2009). 7 by inhibiting the activity of these receptors as membrane E3 ubiquitin ligases involve in the degradation of Fz (Hao et al., 2012; Koo et al., 2012) .
Wnt inhibitors
Wnt inhibitors interact with Wnts and Wnt receptor/co-receptors to modulate Wnt signaling (Cruciat and Niehrs, 2013) . Secreted Frizzled-related protein 1−5 (sFRP1−5) and Wnt inhibitory factor (WIF) bind to Wnts and prevent their interaction with Wnt receptors, resulting in inhibition of Wnt/-catenin-dependent and/or independent signaling. It has been recently suggested that while high levels of sFRPs inhibit Wnt signaling, low levels may enhance it by presenting Wnts to their receptors. The deletion of sFRP1 and sFRP2 phenocopies the mDA neuron differentiation defect observed in the Wnt5a null mice (Kele et al., 2012) , indicating a physiological role of low levels of sFRPs in enhancing Wnt/PCP signaling.
Dickkopfs (Dkk) are best known Wnt inhibitors that bind to Wnt receptors/co-receptors. Dkk1, 2, and 4 bind to Lrp5/6 and another type of receptors, Kremen 1 and 2 (Mao et al., 2002) , forming a ternary complex that inhibits Wnt/-catenin signaling (Ellwanger et al., 2008) . It should be noted that Dkk3 modulates TGF signaling, and Dkk2, in the absence of Kremen, can activate Wnt/-catenin signaling. At a functional level, Dkk1 null mutants lack head structures anterior to the mid-hindbrain boundary and Dkk1 is required for midbrain and limb morphogenesis (Mukhopadhyay et al. 2001; Ribeiro et al., 2011) , emphasizing the importance of Wnt/-catenin inhibition during development. In addition, the Wise/Sclerostin (SOST) family bind to Lrp5/6 and compete for binding with Wnt (Semënov et al., 2005) and Insulin-like growth factor binding protein 1, 2, 4, and 6 (IGFBPs) bind to Fz8 and Lrp6 to block Wnt/β-catenin signaling (Zhu et al., 2008) .
Wnt signaling in mDA neuron development mDA neurons are localized in the ventral part of the midbrain and produce the neurotransmitter dopamine. They were first identified by the content of catecholamines (Dahlström and Fuxe, 1964) and subsequently by the expression of the rate-limiting enzyme in dopamine synthesis, tyrosine hydroxylase (TH) (Hökfelt et al., 1984) . mDA neurons are mainly classified into two anatomically, molecularly, and functionally distinct subtypes, A9 substantia nigra pars compacta (SNc) and A10 ventral tegmental area (VTA).
SNc neurons are positioned anterior and lateral to the VTA, express the G-protein-regulated 8 inward-rectifier potassium channel 2 (GIRK2), project to the dorsal striatum (caudate and putamen) via the nigrostriatal pathway, and control motor function. VTA neurons express calbindin and cholecystokinin (CCK), project to the prefrontal cortex and ventral striatum (nucleus accumbens, amygdala, olfactory tubercle, and prefrontal cortex) via the mesocorticolimbic pathway, and control multiple other functions, such as emotions, motivation, and reward (Carlsson et al., 2001) . SNc and VTA neurons are born in the midbrain floor-plate (mFP). Birth-dating using 3 H-thymidine and TH-immunostaining in mice has shown that while SNc mDA neurons are born between embryonic day (E)10 and E13, VTA mDA neurons are born from E11 to E14 (Bayer et al., 1985) . Genetic fate-mapping experiments have indicated that both SNc and VTA DA neurons are generated by proliferating progenitors in the ventricular zone (VZ) of the mFP, which can be identified by their expression of two key morphogenic factors, Wnt1 (Brown et al., 2011) and another lipid-modified glycoprotein, Sonic hedgehog (Shh) (Joksimovic et al., 2009b; Blaess et al., 2011; Hayes et al., 2011) . Interestingly, Wnt1-expressing progenitors labeled from E7.5 to E13.5 contribute to mDA neurons much more than other cell types in the ventral midbrain (VM) and they contribute to SNc and VTA mDA subtypes with a similar time-line and extent (Brown et al., 2011) . Progenitor cells in the VZ of the mFP, including radial glia-like cells (Bonilla et al., 2008) , undergo neurogenesis and become postmitotic migratory cells. These cells express the chemokine receptor CXCR4 and respond to meningeal-derived CXCL12 by migrating radially from the intermediate zone (IZ) towards the marginal zone (MZ) of the mFP (Yang et al., 2013b) where they become mature mDA neurons.
Wnt1 signaling in mDA neuron development
The VM is patterned by the coordinated action of two signaling centers regulated by transcription factors that produce morphogens and secreted factors that form signaling gradients, such as Shh in the mFP as well as fibroblast growth factor 8 (FGF8) and Wnt1 in the isthmic organizer (IsO) (Acampora et al., 2001; Liu and Joyner, 2001; Wurst and BallyCuif, 2001; Placzek and Briscoe, 2005) . The first factor, Shh, provides ventral identity to cells in the neural tube and its expression in the mFP, from E8.5 to E11.5, is required and sufficient for mDA neuron development in the midbrain-hindbrain region (MHR) (Hynes et al., 1995; Ye et al., 1998) . The second factor, FGF8, is expressed by the hindbrain side of the MH boundary (MHB), contributes to antero-posterior identity, and its intersection with Shh creates the induction site for mDA neurons (Ye et al., 1998) . The third factor, Wnt1, is 9 expressed between E8-8.5 in the presumptive midbrain and extends to the anterior border of the MHB and the roof-plate. Between E10.5-12.5, Wnt1 is detected in two bands at both sides of the mFP (Prakash et al., 2006) . Notably, analysis of Wnt1 null mice revealed that Wnt1 is required for the development of the MHR (McMahon and Bradley, 1990; Thomas and Capecchi, 1990 )and the generation of mDA neurons by a mechanism involving the expression of the homeoprotein engrailed1 (En1) (Danielian et al., 1996) . Interestingly, FGF8 is required to induce or maintain Wnt1 expression and loss of FGF8 also results in a deletion of the MHR (Chi et al., 2003) . Importantly, the capacity of FGF8 to induce ectopic mDA neurons (Ye et al., 1998) was found to require the expression of Wnt1 (Prakash et al., 2006) , indicating that the inductive activity of FGF8 is actually mediated by Wnt1 and that the two key morphogens for mDA neuron development are thus Shh and Wnt1.
Wnt1 conditioned media was found to promote VM progenitor expansion and allow for their subsequent differentiation into mDA neurons (Castelo-Branco et al., 2003) , suggesting that Wnt1 is sufficient for the development of mDA neurons in vitro. The use of GSK3 inhibitors also allowed progenitor to differentiate into mDA neurons in VM cultures (Castelo-Branco et al., 2004) . However, treatment of mDA progenitors with Wnt3a, a Wnt that also activates Wnt/-catenin signaling in mDA neurons (Bryja et al., 2007) , expanded VM progenitors but did not allow their differentiation (Castelo-Branco et al., 2003) .
Interestingly, deletion of the Wnt co-receptor Lrp6 transiently impaired mDA neuron differentiation at E11.5, but not progenitor proliferation (Castelo-Branco et al., 2010) .
Wnt1 overexpression under the control of the endogenous En1 promoter demonstrated that Wnt1 promotes the proliferation of mDA progenitors and their subsequent differentiation in vivo (Panhuysen et al., 2004) . Further analysis of this transgenic mouse revealed a role of Wnt1 in establishing a mDA domain in the FP, as shown by the expression of orthodenticle homologue 2 (Otx2), which in turn represses Nkx2.2 and maintains Wnt1 in the hindbrain (Prakash et al., 2006) . These events are followed at E10.5 by the expression of markers for mDA precursor, such as Aldh1a1, an enzyme involved in retinoic acid synthesis and Nurr1/Nr4a2 (Prakash et al., 2006) , an orphan nuclear receptor required for the terminal differentiation and survival of all mDA neurons (Zetterström et al., 1997) .
Finally, ectopic mDA neurons are induced in the hindbrain FP (Prakash et al., 2006) , as assessed by the subsequent expression of TH and the paired homeodomain transcription factor Pitx3, which is required for mDA differentiation and the survival of only SNc DA neurons (Munckhof et al., 2003; Nunes et al., 2003; Hwang et al., 2003; Smidt et al., 2004; 10 Maxwell et al., 2005) . On the other hand, deletion of Wnt1 resulted in decreased proliferation, but did not affect Otx2 expression, which despite the segmental deletion of the midbrain, was present in the area where very few mDA neurons transiently arise (Prakash et al., 2006; Andersson et al., 2013; Yang et al., 2013a) . Surprisingly, mDA proliferating progenitors, identified by the presence of the LIM homeobox transcription factor 1a (Lmx1a, Andersson et al., 2006a) , are not found in the mFP but rather in the basal plate (BP) where they give rise to few ectopic Nurr1+ and TH+ postmitotic neuroblasts and neurons (Andersson et al., 2013; Yang et al., 2013a) . Interestingly, the expression of Aldh1a1, Pitx3, or the dopamine transporter Slc6a2/Dat was not detected in Wnt1 / mice. However, the few TH+ mDA cells that were detected at E11.5 were lost by E12.5, indicating that mDA neurons were misspecified and subsequently died (Prakash et al., 2006) . In sum, these studies indicated an important role of Wnt1 in expanding and specifying DA progenitors in the mFP, promoting their differentiation, and finally maintaining the survival of mDA neurons
Fgf8 conditional knockout (En1 Cre ) in which Fgf8 is only detected from E8.5 to E9 (Ellisor et al., 2012) . These results indicate that the actual level of Wnt1 signaling (regulated by FGF8) may control mDA neuron subtype specification.
Despite Wnt1 signaling controling most developmental processes in the VM, neither Wnt1 nor catenin/Ctnnb1 deletion leads to any alteration in the expression of the forkhead box A2 (Foxa2) gene (Joksimovic et al., 2009a; Andersson et al., 2013) . Foxa2 is downstream of Shh and together with the forkhead box A1 (Foxa1) gene, is dose-dependently required for DA neurogenesis and differentiation (Ferri et al., 2007) , particularly for the acquisition of a SNc DA neuron phenotype (Stott et al., 2013) . This finding indicates that subtype specification is controlled not only by Otx2 and Wnt1, but also by Foxa1/2, and possibly by the balance between these factors. Another gene that is not under the control of Wnt1/-catenin is the LIM homeobox transcription factor 1b (Lmx1b) (Chung et al., 2009; Joksimovic et al., 2009a) . Conversely, Lmx1b directly regulates Wnt1 (Chung et al., 2009) and maintains the expression of Wnt1 in the isthmic organizer (Adams et al., 2000) .
Surprisingly, Lmx1b null mice showed a relatively mild phenotype consisting of a reduced expression of Wnt1, Pitx3, and TH, followed by cell loss by E16, as Nurr1+ cells fail to initiate the expression of TH and Pitx3 (Smidt et al., 2000; Deng et al., 2012) . However, double Lmx1a and Lmx1b null mice revealed a loss of Wnt1 expression in the mFP, a loss of proliferative progenitors, and a decrease in postmitotic Nurr1+, Pitx3+, and TH+ cells (Deng et al., 2011; Yan et al., 2011) . This phenotype, which largely resembles that of Wnt1 / mice, indicates that Lmx1a and Lmx1b redundantly regulate key aspects of mDA neuron development.
Recent ChIP experiments have allowed us to gain even further understanding of the developmental pathways regulated by Wnt1 during mDA neuron development. First, an autoregulatory loop in which Wnt1/-catenin and Lmx1b directly regulate and are regulated by Lmx1a was described (Chung et al., 2009) . In this network, -catenin directly regulated Otx2 and importantly, Lmx1a/b controlled mDA neuron differentiation and survival at least in part by a direct regulation of Nurr1 and Pitx3. More recently, Foxa2 was found to directly regulate in a positive manner not only Shh, but also Lmx1a/b, Msx1, and Ferd3l/Nato3, a basic helix-loop-helix gene that can regulate Ngn2 (Metzacopian et al., 2012) . In sum, all evidence currently available indicates that Wnt1 is absolutely required for the development of the MHR and regulates multiple steps in mDA development including patterning, specification, proliferation, neurogenesis, differentiation, and survival.
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Recent studies indicate that the development of mDA neurons greatly depends on the balance between two regulatory networks described above, the Shh−Foxa2 and the Wnt1/-catenin−Lmx1a−Lmx1b−Otx2 network.
Wnt2
Another Wnt capable of activating the Wnt/-catenin pathway is Wnt2, which binds and activates Lrp5/6 resulting in the phosphorylation of Lrp5/6 and Dvl-2/3, as well as increased levels of dephosphorylated active β-catenin in mDA cells (Sousa et al., 2010) .
Administration of purified Wnt2 protein to VM progenitor culture increased the proliferation, the number of Nurr1+ cells, and the proportion of mDA neurons (%TH/Tuj1) in the culture. Moreover, deletion of Wnt2 decreased progenitor proliferation in the VM resulting in a reduction in the number of Nurr1+ and TH+ cells (Sousa et al., 2010) , indicating a role of this Wnt in VM and mDA neuron development, which was similar to that of Lrp6 (Castelo-Branco et al., 2010) .
Wnt5a in mDA neuron development
Wnt5a is the second best studied Wnt in the developing VM. Wnt5a is expressed in this region from E9.5, being progressively restricted to the midline, and expressed in few TH+ cells in the VTA by E13.5. Notably, Wnt5a is expressed not only in VZ progenitors of the mFP and BP, but also in Nurr1+ and TH+ cells in the mFP at E12.5 (Andersson et al., 2008) , suggesting a specific function of this Wnt in mDA neuron development. Wnt5a is expressed by other cell types, such as midbrain radial glia and astrocytes as well as meningeal cells (Hayashi et al., 2008) . Gain-of-function experiments have revealed that Wnt5a decreases the proliferation of mDA progenitors, enhances the differentiation of Nurr1+TH-cells into Nurr1+TH+ neurons, and promotes neuritogenesis of TH+ cells in vitro (Castelo-Branco et al., 2003; Schulte et al., 2005; Bryja et al., 2007) . Accordingly, deletion of Wnt5a results in enhanced progenitor proliferation, which is accompanied by an overproduction of Nurr1+TH-postmitotic cells and a nearly normal number of TH+ cells (Andersson et al., 2008) . Moreover, Wnt5a mutant mice exhibited morphogenesis defects, manifested by a lateral expansion of the Shh, Foxa2, Lmx1a, and Indeed, Wnt5a does not activate Wnt/-catenin signaling in DA cells, but rather Wnt/PCP/Rac1 signaling (Schulte et al., 2005; Andersson et al., 2008; Bryja et al., 2008; Cajanek et al., 2013) , a pathway that has been recently involved in the regulation of DA axon growth and guidance both in vitro and in vivo (Blakely et al., 2011) .
Moreover, deletion of the Wnt receptor Fz3, the Wnt/PCP co-receptor Celsr3 or Vangl2 (Looptail mice) resulted in decreased rostral and aberrant caudal DA projections, as well as lack of innervation of the striatum in Fz3 and Celsr3 mutants (Fenstemaker et al., 2010 ). Fz3 and 6 have also been shown to be required for midbrain morphogenesis (Stuebner et al., 2010) . Additionally, the Wnt co-receptor Ryk was recently found to mediate some effects of Wnt5a on mDA neurons in vitro and regulate mDA neurogenesis as well as axon morphogenesis in vivo (Blakely et al., 2013) .
Interactions between Wnt1 and Wnt5a
Wnt1 and Wnt5a are known to activate Wnt/β-catenin and Wnt/PCP signaling pathways, respectively in mDA neurons. Individual deletion of Wnt1 or Wnt5a revealed that these two Wnts mainly regulate different functions during mDA neuron development (Inestrosa and Arenas, 2010) . One clear example is the regulation of mDA progenitor proliferation, which is increased by Wnt1 (Andersson et al., 2013) and decreased by Wnt5a (Andersson et al., 2008) , and as expected, the loss of proliferation in Wnt1 null embryos can be compensated by the additional deletion of Wnt5a in double knockout mice (Andersson et al., 2013) ( Figure 1) . However, analysis of double Wnt1 and Wnt5a knockout mice also revealed an unexpected level of cooperation between these two Wnts to potentiate each other in a manner that was not anticipated by the analysis of individual null mutant mice. For instance, deletion of Wnt1 and Wnt5a revealed that the loss of Wnt1 worsened the Wnt5a/PCP morphogenesis phenotypes observed in Wnt5a −/− mice, resulting in increased mediolateral and dorsoventral distribution of DA neurons as well as A-P shortening of the TH+ domain in double null mutants (Andersson et al., 2013) . Similarly, while loss of Wnt5a did not affect neurogenesis or the number of TH+ mDA neurons (Andersson et al., 2008) , deletion of Wnt5a worsened the DA neurogenesis and differentiation phenotypes in double knockout embryos than those in Wnt1 −/− mice (Andersson et al., 2013) . Combined, these results indicate that Wnt1 and Wnt5a interact and cooperate in a more extensive and complex manner than anticipated to regulate mDA neuron development (Figure 1 ). This 14 cooperation can be explained by some shared signaling components between the Wnt/-catenin and Wnt/PCP pathways, such as Fz and Dvl, but also by their interaction with common targets involved in the regulation of the cytoskeleton, cell cycle, or neurogenesis.
Future experiments should focus on the identification of such molecular targets that are common to both pathways and key for the development of mDA neurons.
Wnt inhibitors
Wnt inhibitors are also capable of regulating mDA neuron development. Surprisingly, deletion of Dkk1 or sFRP1/2 did not result in Wnt gain-of-function phenotypes, but rather lossoffunction-like phenotypes. Deletion of Dkk1, which results in the loss of all brain structures anterior to the midbrain, caused a very severe loss of mDA neurons and morphogenesis defects by E17.5 (Ribeiro et al., 2011) . Moreover, heterozygous embryos exhibited differentiation defects at E13.5 resulting in a reduced number of mDA neurons that persisted at E17.5. These results show that Dkk1 is required for mDA differentiation and morphogenesis. Similarly, double sFRP1;sFRP2 null mice phenocopied the differentiation and the morphogenesis phenotypes of the Wnt5a null mutant (Kele et al., 2012) , indicating that the low endogenous levels of these two sFRPs in the developing midbrain are actually required for Wnt/PCP signaling. Accordingly, in vitro treatment of primary midbrain progenitors with low concentrations of sFRP2 promoted mDA neuron differentiation and only in the presence of very high concentrations of sFRPs did they act as Wnt inhibitors (Kele et al., 2012) . These results emphasize the importance of the so-called Wnt inhibitors to actually maintain and modulate Wnt signaling to promote proper mDA neuron development.
Parkinson's disease (PD)
PD is the most common motor neurodegenerative disorder. At clinical level, PD is characterized by tremor, rigidity, akinesia, postural instability, and gait disturbances. The cause of PD is unknown in the majority of the cases, being less than 10% familial genetic forms and the rest considered as sporadic PD. It is currently thought that environmental factors, e.g. pesticides (rotenone) or toxins (MPTP), together with genetic factors play a role in PD (Thomas and Beal, 2007) . Genetic forms of PD are rare, but they have provided very valuable information about the genes and signaling pathways involved. Mutations have been identified in genes encoding either structural cellular components (-synuclein) or signaling components including kinases, such as leucine-rich repeat kinase 2 (LRRK2) and PTEN-induced putative kinase 1 (PINK1), ubiquitin ligases (Parkin), mitochondrial proteins (DJ1), and lysosomal proteins, such as glucocerebrosidase (GBA1). While some of these mutations are associated with autosomal dominant PD (-synuclein and LRRK2), others are recessive (PINK1, Parkin, and DJ1) or risk (GBA1) alleles (Singleton et al., 2013) . The penetrance of these mutations is variable, for instance, increasing with age in the case of LRRK2. These mutations, as well as environmental factors, seem to affect common cellular mechanisms leading to mitochondrial dysfunction, oxidative stress, protein misfolding, and impairment of the ubiquitin−proteasome and autophagy−lysosomal systems. Interestingly, several disease genes are also linked to Wnt signaling (Inestrosa and Arenas, 2010 ) and directly interact with Wnt signaling components, such as Parkin, a ubiquitin ligase for -catenin (Rawal et al., 2009) , LRRK2 that interacts with Lrp6, Axin1, GSK3β, and β-catenin (Berwick and Harvey, 2012) , as well as Dvl 1−3 (Sancho et al., 2009 ).
Pathologically, PD is characterized by the degeneration of neurons, in particular SNc DA neurons, and the presence of abnormal fibrillar cytoplasmic inclusions rich in -synuclein and ubiquitin, called Lewy bodies, in surviving neurons of both central and peripheral nervous system (Jellinger, 2012) . Subcellularly, degeneration appears first at the synapse and then extends in a retrograde fashion to the rest of the neuron. In the nigrostriatal system, when this process leads to a severe loss of the neurotransmitter dopamine in the striatum exceeding 60%, the first motor symptoms of PD appear (Jellinger, 2012) . Thus, by the time of diagnosis, a significant level of neurodegeneration has already occurred, which limits the efficacy of current therapeutic interventions based on increasing dopaminergic transmission with dopaminergic agonists or L-DOPA, a precursor of dopamine, or alternatively, inhibiting overactive pathways by surgically implanting electrodes for deep brain stimulation (Lees et al., 2009 ). The most common and efficacious symptomatic treatment today is L-DOPA. However, its long-term use leads to adverse effects, such as dyskinesias, and decreasing efficacy due to the progressive loss of DA neurons remaining in the brain, thus prompting the development of regenerative medicine strategies for treating PD.
Wnt signaling in regenerative medicine strategies for PD
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Studies of fetal tissue transplantation in PD patients has indicated that cell replacement therapy is a viable therapeutic option by showing that mDA neurons morphologically and functionally integrate in the striatum and the circuitry of patients. However, clinical outcomes are variabledue to multiple factors including the way to prepare tissue prior to transplantation, the amount of cells, the position of the graft, the duration of immunosuppression, and patient selection Björklund, 2004, 2011) . Notably, younger patients with motor forms and pathology restricted to the striatum benefit most, and the optimal symptomatic relief lasted for up to 16 years without L-DOPA. However, 15% of the patients developed graft-induced dyskinesias that are associated with the presence of serotonin neurons in grafts and can be blocked by 5HT1A agonists (Politis et al., 2010) . Lewy bodies, the hallmark of PD, were found in fetal cells after one decade posttransplantation but did not hamper long-term improvements in PD patients (Dunnet et al., 2001; Björklund, 2004, 2011; Arenas, 2010) . The main obstacle for the therapeutic application of human fetal VM tissue is the poor tissue availability and the difficulties to standardize fetal tissue prior to grafting. It is currently thought that neural stem cells derived from human VM tissue or pluripotent stem cells are better sources for cell replacement therapy, since they are expandable and allow for standardization and quality control.
Stem cellderived mDA neuron transplant
As Wnts are key building blocks in neural development, in particular the development of mDA neurons, they thus become very attractive basic tools to create stem cell-derived mDA neurons. One strategy targeting the expansion of midbrain stem/progenitor cells present in the VM tissue and their subsequent differentiation was first developed for rodent VM tissue grown as neurospheres (Parish et al., 2008) and recently successfully applied to improve the quantity and quality of human mDA neurons derived from human fetal midbrain tissue (Ribeiro et al., 2012) . Briefly, bFGF in combination with Shh and FGF8 were used to increase properties of the cells. This strategy reduces the number of human fetal tissues required for transplantation, and may thus allow development of a more rapid cell transplantation in PD patients. Human fetal tissue from the midbrain-hindbrain region has also been used for deriving other immortalized (Courtois et al., 2010) or non-immortalized cell lines (Tailor et al., 2013) . But the possible application of Wnts to these cells has not yet been examined.
Wnt signaling has been reported to play a role in the maintenance and early differentiation of embryonic stem (ES) cells (Merrill, 2012; Holland et al., 2013) . Here we exclusively focus on the role of Wnt signaling starting in already neuralized ES cells. A combination of Wnt5a and FGF20 treatment was found to promote the in vitro differentiation of parthenogenetic primate ES cells into mDA neurons (Sanchez-Pernaute et al., 2008) . Notably, when these cells were transplanted into a rodent model of PD, they survived better and induced functional recovery, as assessed by motor function, to a greater extent than control ES cells.
It is important to note that in vitro treatment of mouse ES (mES) cells with inhibitors of the
Wnt/-catenin pathway similarly promotes mDA differentiation. Several studies have shown that the Wnt/-catenin and Wnt/PCP pathways are in balance and inhibition of the former pathway leads to activation of the latter (Topol et al., 2003; Veeman et al., 2003; Tahinci et al., 2007; Bryja et al., 2009 ). Consistently, Dkk1 treatment, deletion of Wnt1 or Lrp6, or treatment with low concentrations of sFRP1 or sFRP2 was found to increase mDA differentiation of mES cells (Cajanek et al., 2009; Kele et al., 2012) . Interestingly, higher or lower concentrations of sFRP1 or sFRP2 were less effective or completely ineffective (Kele et al., 2012) , indicating that a very precise level of Wnt signaling is required for proper mDA differentiation.
The balance between Wnt/-catenin and Wnt/PCP signaling, for what we know from developmental studies, changes at different stages of mDA neuron development. It is thus conceivable that similar variations might be necessary to improve current protocols for generating mDA neurons from stem cells. In a recent attempt, a sequential treatment with Wnt3a first to activate Wnt/-catenin signaling during mDA progenitor proliferation, and then Wnt5a to activate Wnt/PCP signalling and promote mDA differentiation, was tested in both mouse VM neurospheres and mES cells (Andersson et al., 2013) . While Wnt5a alone increased the number of TH+ cells, Wnt3a alone did not. However, sequential Wnt treatment significantly increased the proportion of TH+ cells/TuJ1+ in both VM neurosphere and mES cultures by 80%, compared with either Wnt5a or Wnt3a treatment alone (Andersson et al., 2013) . It also increased the number of mES-derived TH+ cells by guest on November 8, 2016
http://jmcb.oxfordjournals.org/ Downloaded from expressing typical midbrain markers (Lmx1a, Foxa2, Nurr1, and Pitx3), compared with control cells treated with Shh, FGF8, and bFGF, followed by ascorbic acid, BDNF, and GDNF, but without Wnts. Moreover, double knockout for Wnt1 and Wnt5a shows a greater loss of mDA neurons, compared with each individual knockout (Andersson et al., 2013) . These results indicate that the use of Wnts in developmentally-based protocols has the potential to improve both the quantity and quality of mDA neurons. However, this dual Wnt protocol
has not yet been implemented in human stem cells or animal models of PD, both of which are essential for determining the function and therapeutic potential. (Kriks et al., 2011; Kirkeby et al., 2012; Xi et al., 2012) . This protocol used Smad inhibitors for neural induction, Shh and FGF8 for ventralization and midbrain patterning, CHIR99021 to activate Wnt/β-catenin signalling and induce a midbrain floor plate identity, and other survival and differentiation factors. It resulted in 70%−80% mDA neurons with a very high degree of colocalization of Lmx1a and Foxa2, indicating optimal activation of the Wnt1/Lmx1a and Shh/Foxa2 pathways. Kirkeby et al. (2012) also found that low and high concentrations of GSK3β inhibitors induced diencephalic and hindbrain cells, respectively, while intermediate concentrations resulted in cells with midbrain identity. These results represent an important breakthrough for the advancement of cell replacement therapies and regenerative medicine for PD, As mDA neurons produced by this protocol co-expressed typical midbrain markers, exhibited appropriate electrophysiological properties, were capable of releasing dopamine, innervated the target tissue, induced behavioral motor recovery in diverse animal models of PD, and did not lead to neural overgrowth (Kriks et al., 2011; Kirkeby et al., 2012) .However, in addition to -catenin and Lrp6, GSK3 also phosphorylates other pathway components (Hur and Zhou, 2010) including Gli (Smelkinson et al., 2007) , Smad (Eivers et al., 2008) , nuclear receptors (Burns and Vanden Heuvel, 2007) , and transcription factors, such as basic helix-loop-helix (Ma et al., 2008) and CREB, all of which are important for mDA neuron development. Moreover, GSK3 can regulate -and -secretases, which are involved in Notch signaling and Alzheimer's disease (Ly et al., 2013) . Thus, those observed effects of GSK3 inhibitors could also be attributed to Shh, BMP/TGF or neurotrophin signaling. Future studies should aim at using more specific Wnt/-catenin activators and explore the involvement of Wnt-independent GSK3-regulated pathways.
These studies may contribute to develop more effective protocols for the generation of mDA neurons from stem cells and improve their applications in cell replacement therapy or drug development (Figure 2 ).
Reprogramming
Direct reprogramming has evolved from the initial work by Takahashi and Yamanaka (2006) . In direct reprogramming, neurons are generated from other somatic cells, such as astrocytes or fibroblasts, by the expression of key master transcription factors and/or microRNAs relevant to the cell type being generated (Ladewig et al., 2013) . Overexpression of the transcription factor Pax6 has been used to reprogram astrocytes into cortical neurons (Heins et al., 2002) . Combination of factors, such as Brn2, Ascl1, and Mytl1 (BAM) have been used to reprogram completely unrelated cells, such as fibroblasts, into electrophysiologically functional cortical neurons (Vierbuchen et al., 2010) .
More recently, rodent and human fibroblasts were first reprogrammed into induced DA (iDA) neurons by different combinations of transcription factors relevant for the neuronal reprogramming (Ascl1) and the induction of mDA neurons, such as Lmx1a or Nurr1. Specific combinations used for iDA reprogramming include Lmx1a, Ascl1/Mash1, and Nr4a2/Nurr1 (Caiazzo et al., 2011 ), Brn2, Ascl1, Mytl1, Lmx1a, and Foxa2 (Pfisterer et al., 2011 ), or Ascl1, Lmx1a, Foxa2, Nurr1, En1, and Pitx3 (Kim et al., 2011 . These studies also examined the transplantability of iDA cells, which in the case of rodent iDA cells led to clear host innervation and behavioral recovery in an animal model of PD (Kim et al., 2011) .
Interestingly, the GSK3 inhibitor CHIR99021 was used in combination with Smad inhibitors and two proneural transcription factors, Ascl1 and Ngn2, in direct reprogramming of fibroblasts into neurons (Ladewig et al., 2012) . This method resulted in a remarkable increase in neuronal yield of 150−200% and a final purity of 70%−80%. In the future, whether GSK3 inhibitors can also increase the number, phenotypic properties, and transplantability of directly reprogrammed iDA neurons will be examined.
In sum, iDA neurons are promising candidates for cell replacement therapy (Figure 2) . Importantly, the generation of iDA cells, unlike iPS cells, does not involve creating proliferative cells and no cell overgrowth has been detected. Finally, the direct in vivo reprogramming of endogenous brain striatal cells in situ (Torper et al., 2013) provides an additional reprogramming approach that gene therapy rather than cell transplantation is used (Figure 2) . So far the efficiency of direct in vivo reprogramming is low, but the full potential of this attractive method remains yet to be explored.
Disease modeling and drug discovery
It is worth mentioning that reprogrammed cells obtained from PD patients and differentiated into mDA neurons are also ideal tools for disease modeling and drug discovery ( Figure 2) . Indeed, human iPS cells derived from different forms of PD patients are currently used to investigate the pathogenesis of human PD and screen for drugs that impact on defined pathogenic mechanisms. In this context, Wnt signaling may play a role in Wnt-based protocols for the differentiation of these iPS cells, and thus modeling PD in vitro, since several PD-associated proteins interact with Wnt signaling components and modulate Wnt signaling (Rawal et al., 2009; Sancho et al., 2009; Inestrosa and Arenas 2010; Berwick and Harvey, 2012) . For instance, iPS cells derived from PD patients with LRRK2 or Parkin mutations are very interesting regenerative medicine tools to understand the pathogenesis of PD and develop novel drugs combating this devastating disease.
Future directions
During the last years, many small molecules capable of modulating Wnt signaling have become available (see details in Supplementary material), . while those capable of specifically and selectively activating certain branches of Wnt signaling and unaffecting other pathways are still lacking. This is particularly for activators of Wnt/PCP pathway where only a Wnt5a-mimetic small peptide was described (Säfholm et al., 2006) . Additionally, the variability in quality and activity of current commercially available Wnt5a protein makes it difficult to generate stem-or reprogrammed-derived mDA neurons with a standard protocol. One strategy is to develop small molecules or biologicals, such as antibodies capable of inhibiting syndecan-mediated internalization of R-spondins, to potentiate Wnt/PCP signaling (Ohkawara et al., 2011) . Other alternatives involve activating Wnt co-receptors playing a role in Wnt/PCP signaling (Ror1/2) or selectively modulating Dvl sites involved in Wnt/PCP signaling. It is also necessary to identify more selective small molecular activators of Wnt/-catenin signaling. commonly used GSK3 inhibitors have off target effects (Bain et al., 2007) and affect all different activities regulated by GSK3 including Wnt-unrelated functions (Hur and Zhou, 2010) . One candidate is Tiki1 inhibitors that inhibit the proteolytic cleavage of Wnt . Others can involve inhibiting Dkk1 binding to Lrp5/6 and Kremen 1−2 or inhibiting the sequestration of Lrp5/6 away from Fz. Within the field of regenerative medicine and PD, the development of small molecules capable of selectively and efficiently modulating different branches of Wnt signaling is likely to have a profound impact on our capacity to regulate stem cell behavior and reprogramming, thus contributing to cell replacement and drug development strategies. For cell transplantation, it is currently thought that human PS cells are the optimal source of mDA neurons because of their capacity to engraft and induce recovery of motor function in animal models of PD (Kriks et al., 2011; Kirkeby et al., 2012) . Compared with iPS cells, ES cells are preferred for cell replacement therapy, since they are not genetically modified and their epigenetic state is more stable and homogenous (Cahan and Daley, 2013) . Currently available stem cell-derived mDA neurons contain both SNc and VTA mDA neurons. As discussed before, several factors including Wnt signaling control the specification for SNc or VTA subtype. In the future, it will be very important to develop protocols that would promote the differentiation towards SNc mDA neurons. In addition, shorter robust protocols for the generation of SNc mDA neurons are required, as current ones using ES cells are relatively long. One option is to use PS cell-derived neuralized cells that could be used as a platform for mDA differentiation in shorter time. Potential candidates are PS cell-derived long-term neuroepithelial stem cells, which can be differentiated into mDA neurons (Koch et al., 2009; Falk et al., 2012) . However, to date, Therefore, Wnt1 and Wnt5a show a synergism for morphogenesis, neurogenesis, and differentiation, but a competition for proliferation. This figure is modified from author summary in Andersson et al. (2013) . 
